Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

DelveInsight's Sarcopenia Market Insights report includes a comprehensive understanding of current treatment practices, sarcopenia emerging drugs, market share of individual therapies, and current and ...

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.

Review the current Novo Nordisk AS ADR (NVO:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if NVO is the best investment for you.

DAKAR (Reuters) -Malian tax officials have reopened Barrick Mining's office in the capital under a court-appointed ...